https://www.esmo.org/oncology-news/trastuzumab-deruxtecan-prolongs-os-in-second-line-treatment-for-patients-with-her2-positive-metastatic-gastric-or-gej-adenocarcinoma
Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive...
second line treatment
https://pmc.ncbi.nlm.nih.gov/articles/PMC12657762/
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for...
Atezolizumab plus bevacizumab (A+B) is a standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). However, optimal sequencing...
second line treatment